The anti‐fibrotic actions of relaxin are mediated through AT2R‐associated protein phosphatases via RXFP1‐AT2R functional crosstalk in human cardiac myofibroblasts. Issue 6 (16th April 2020)

• Record Type: Journal Article
• Authors: Wang, Chao; Pinar, Anita A.; Widdop, Robert E.; Hossain, Mohammed A.; Bathgate, Ross A. D.; Denton, Kate M.; Kemp‐Harper, Barbara K.; Samuel, Chrishan S.
• Is Part Of: FASEB journal. Volume 34:Issue 6(2020)
• Page Start: 8217
• Page End: 8233
• Publication Date: 2020-04-16
• Subjects: AT2 receptor -- cardiac fibrosis -- myofibroblasts -- phosphatases -- RXFP1; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201902506R
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: Fibrosis is a hallmark of several cardiovascular diseases. The relaxin family peptide receptor 1 (RXFP1) agonist, relaxin, has rapidly occurring anti‐fibrotic actions which are mediated through RXFP1 and angiotensin II receptor crosstalk on renal and cardiac myofibroblasts. Here, we investigated whether this would allow relaxin to indirectly activate angiotensin II type 2 receptor (AT2 R)‐specific signal transduction in primary human cardiac myofibroblasts (HCMFs). The anti‐fibrotic effects of recombinant human relaxin (RLX; 16.8 nM) or the AT2 R‐agonist, Compound 21 (C21; 1 μM), were evaluated in TGF‐β1‐stimulated HCMFs, in the absence or presence of an RXFP1 antagonist (1 μM) or AT2 R antagonist (0.1 μM) to confirm RXFP1‐AT2 R crosstalk. Competition binding for RXFP1 was determined. Western blotting was performed to determine which AT2 R‐specific protein phosphatases were expressed by HCMFs; then, the anti‐fibrotic effects of RLX and/or C21 were evaluated in the absence or presence of pharmacological inhibition (NSC95397 (1 μM) for MKP‐1; okadaic acid (10 nM) for PP2A) or siRNA‐knockdown of these phosphatases after 72 hours. The RLX‐ or C21‐induced increase in ERK1/2 and nNOS phosphorylation, and decrease in α‐SMA (myofibroblast differentiation) and collagen‐I expression by HCMFs was abrogated by pharmacological blockade of RXFP1 or the AT2 R, confirming RXFP1‐AT2 R crosstalk in these cells. HCMFs were found to express AT2 R‐dependent MKP‐1 and PP2A phosphatases, while pharmacological blockade or siRNA‐knockdown of either phosphatase also abolished RLX and/or C21 signal transduction in HCMFs (all P < .05 vs RLX or C21 alone). These findings demonstrated that RLX can indirectly activate AT2 R‐dependent phosphatase activity in HCMFs by signaling through RXFP1‐AT2 R crosstalk, which have important therapeutic implications for its anti‐fibrotic actions.